peptide fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
== Veterinary use == Hydromorphone is used as an intravenous analgesic in cats and dogs. Hydromorphone's potency is 5–10 times greater than morphine when given intravenously and the length of effect is dose dependent with times ranging 1–8 hours. Anaesthetic recovery can be prolonged from long use of hydromorphone. Hydromorphone is not useful compared to morphine when given subcutaenously in cats or epidurally in cats and dogs. Hydromorphone can provide analgesia up to 12 hours when given intravenously in horses and is also effective when given intramuscular. Hydromorphone has minimal adverse effects in horses when compared to other opioids such as morphine.
Nivolumab (Opdivo), a PD-1 inhibitor (2018) Atezolizumab (Tecentriq), a PD-L1 inhibitor (2018) Tarlatamab, a bi-specific T-cell engager (2024) Canadian regulator rejected funding Tecentriq (Atezolizumab) for extensive-stage small-cell lung cancer in 2020 "as too costly" followed by the United Kingdom also citing "drug's cost-effectiveness."
Sulfuric acid is a key substance in the chemical industry. It is most commonly used in fertilizer manufacture, but is also important in mineral processing, oil refining, wastewater treating, and chemical synthesis. It has a wide range of applications, including in domestic acidic drain cleaners, as an electrolyte in lead-acid batteries, as a dehydrating compound, and in various cleaning agents.
During the late-1920s, the Rockefeller Foundation created the Medical Sciences Division, which emerged from the former Division of Medical Education. The division was led by Richard M. Pearce until his death in 1930, to which Alan Gregg succeeded him until 1945. During this period, the Division of Medical Sciences made contributions to research across several fields of psychiatry. In 1935 the foundation granted $100000 to the Institute for Psychoanalysis in Chicago. This grant was renewed in 1938, with payments extending into the early-1940s. This division funded women's contraception and the human reproductive system in general, but also was involved in funding controversial eugenics research. Other funding went into endocrinology departments in American universities, human heredity, mammalian biology, human physiology and anatomy, psychology, and the studies of human sexual behavior by Alfred Kinsey. In the interwar years, the foundation funded public health, nursing, and social work in Eastern and Central Europe. In 1950, the foundation expanded their international program of virus research, establishing field laboratories in Poona, India, Trinidad, Belém, Brazil, Johannesburg, South Africa, Cairo, Egypt, Ibadan, Nigeria, and Cali, Colombia, among others. The foundation funded research into the identification of human viruses, techniques for virus identification, and arthropod-borne viruses. Bristol-Myers Squibb, Johns Hopkins University and the Rockefeller Foundation are currently the subject of a $1 billion lawsuit from Guatemala for "roles in a 1940s U.S.
== Structure == Delta hexatoxin Hv1 is a tightly folded polypeptide that contains a chain of 42 amino acid residues and has the chemical formula C206H318N58O60S9. The amino acid sequence of delta hexatoxin Hv1 is:The tertiary structure of δ-ACTX-Hv1 contains a core β region that is made up of the residues Cys1–Cys8, Cys14–Val21, and Ser30–Ser33, with Tyr22–Gly29 protruding outwards. The β region has a three-stranded antiparallel β sheet comprising Asn6–Trp7 (β1), Met18–Val21 (β2), and Ser30–Ser33 (β3). The C-terminal end of the short β1 is held in place by a bifurcated hydrogen bond between the Cys8 amide proton and the carbonyl oxygens of the two residues preceding β strand 3 (Gln28 and Gly29). The β region also contains type II β turns at Lys3–Asn6 and Cys15–Met18 with a rare cis peptide bond at Cys16–Met 17. The nonpolar C-terminal 310 helix formed by Ile35–Lys41, bordering Lys40 and Lys41 and connecting to β region with a disulphide bond next to a β turn. The β region contains hydrophobic cysteine sidechains bordered by a lysine sidechain.Three of the four disulphide bonds form the ICK. The structure of the cystine knot motif found in versutoxin is similar to the one found in gurmarin, a 35-residue plant polypeptide used to test the inhibition of sweet taste receptors.
Sources: en.wikipedia.org
Through-bond interactions relate to structural connectivity of the atoms and provide information about which ones are directly connected to each other, connected by way of a single other intermediate atom, etc. Through-space interactions relate to actual geometric distances and angles, including effects of dipolar coupling and the nuclear Overhauser effect. Although the fundamental concept of 2D-FT NMR was proposed by Jean Jeener from the Free University of Brussels at an international conference, this idea was largely developed by Richard Ernst, who won the 1991 Nobel prize in Chemistry for his work in FT NMR, including multi-dimensional FT NMR, and especially 2D-FT NMR of small molecules. Multi-dimensional FT NMR experiments were then further developed into powerful methodologies for studying molecules in solution, in particular for the determination of the structure of biopolymers such as proteins or even small nucleic acids. In 2002 Kurt Wüthrich shared the Nobel Prize in Chemistry (with John Bennett Fenn and Koichi Tanaka) for his work with protein FT NMR in solution.
== Epidemiology == In the United States, approximately 550,000 people die each year from heart-related arterial embolism and thrombosis. Approximately 250,000 of these individuals are female, and approximately 100,000 of all these deaths are considered premature, that is, prior to the age of average life expectancy.
Looking Glass (or Operation Looking Glass) is the historic code name for an airborne command and control center operated by the United States. Since 2016 it has been referred to as the ABNCP (Airborne National Command Post). It provides command and control of U.S. nuclear forces in the event that ground-based command centers have been destroyed or otherwise rendered inoperable. In such an event, the general officer aboard the Looking Glass serves as the Airborne Emergency Action Officer (AEAO), and by law assumes the authority of the National Command Authority and could command execution of nuclear attacks. The AEAO is supported by a battle staff of approximately 20 people, with another dozen responsible for the operation of the aircraft systems. The name Looking Glass, which is another name for a mirror, was chosen for the Airborne Command Post because the mission operates in parallel with the underground command post at Offutt Air Force Base.
=== Fabrication === The electrostatic potential needed to create a quantum dot can be realized with several methods. These include external electrodes, doping, strain, or impurities. Self-assembled quantum dots are typically between 5 and 50 nm in size. Quantum dots defined by lithographically patterned gate electrodes, or by etching on two-dimensional electron gases in semiconductor heterostructures can have lateral dimensions between 20 and 100 nm. The formation of quantum dots can be spontaneous when a semiconductor material is deposited on a substrate and a difference in lattice space exists between them. By means of advanced nanofabrication technologies it is possible to manipulate properties of the quantum dots, such as their interactions, shape, size and transparency. For example, when negative voltage is applied to a metal gate around a QD, as response, its diameter starts to be gradually squeezed, as a consequence, the number of electrons on the dot starts to decrease one by one, this could be made until there are no more left. The previous property allows to record the current flow as the number of electrons on the dot, this implies that the energy variates.
== Toxicity == The biological function of TsPep2 is not clear yet, except from a small displacement on the 125I-KTX binding site on rat brain synaptosomes. However, it has been shown that this peptide is not toxic to mice. The LD50 of TsPep2 is currently unknown.
Sources: en.wikipedia.org
=== Development === Developmentally, the majority of mucous membranes are of endodermal origin. Exceptions include the palate, cheeks, floor of the mouth, gums, lips and the portion of the anal canal below the pectinate line, which are all ectodermal in origin.
The widespread use of children in cocoa production is controversial, not only for the concerns about child labor and exploitation, but also because according to a 2002 estimate, up to 12,000 of the 200,000 children then working in the Ivory Coast cocoa industry may have been victims of trafficking or slavery. Most attention on this subject has focused on West Africa, which collectively supplies 69 percent of the world's cocoa, and the Ivory Coast in particular, which supplies 35 percent of the world's cocoa. Thirty percent of children under age 15 in sub-Saharan Africa are child laborers, mostly in agricultural activities including cocoa farming. Major chocolate producers, such as Nestlé, buy cocoa at commodities exchanges where Ivorian cocoa is mixed with other cocoa. As of 2017, approximately 2.1 million children in Ghana and Ivory Coast were involved in farming cocoa, carrying heavy loads, clearing forests, and being exposed to pesticides. As of 2018, a 3-year pilot program – conducted by Nestlé with 26,000 farmers mostly located in Ivory Coast – observed a 51% decrease in the number of children doing hazardous jobs in cocoa farming. The US Department of Labor formed the Child Labor Cocoa Coordinating Group as a public-private partnership with the governments of Ghana and Ivory Coast to address child labor practices in the cocoa industry.
==== Biomarkers of cereal presence in archaeological pottery ==== Recently, alkylresorcinols have been widely recognised as a biomarker for the presence of cereals in archaeological pottery. They were previously found in a well-preserved Bronze Age wooden container from Switzerland, and coarse ware vessels from a Roman cavalry barrack at Vindolanda. A study demonstrated that the survival of ARs is highly dependent on the cooking procedures and burial conditions. However, if recoverable, analysis of these phenolic lipids in archaeological contexts is valuable as it can help explain the uptake and spread of cereal processing of past communities in particular regions.
Histology image: 09601loa – Histology Learning System at Boston University – "Digestive System: Oral Cavity and Teeth – lip, oral mucosa" Histology image: 95_04 at the University of Oklahoma Health Sciences Center – "Lip" Histology image: 95_07 at the University of Oklahoma Health Sciences Center – "Lip" Common Dental and Oral Mucosal Disorders, Duke University at https://web.archive.org/web/20160303221658/http://pamodules.mc.duke.edu/Oral_Health/Print.asp?CourseNum=1&LessonNum=3
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.